Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesIron chelation and multiple sclerosisEvidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in ratsIron in chronic brain disorders: imaging and neurotherapeutic implications.Pathogenic implications of iron accumulation in multiple sclerosis.Role of oxygen free radicals in retinal damage associated with experimental uveitisTreatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effectsThe iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental miceQuantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging.Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis.Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic miceHypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.Hypoxic Adaptation in the Nervous System: Promise for Novel Therapeutics for Acute and Chronic Neurodegeneration.In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.Free radicals in disease processes: a compilation of cause and consequence.Relationship of iron to oligodendrocytes and myelination.Deep gray matter T2 hypointensity correlates with disability in a murine model of MS.Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender DifferencesThe cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.Antioxidant enzyme suppression of demyelination in experimental optic neuritis.Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis.Desferrioxamine in chronic progressive multiple sclerosis: a pilot study.Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?
P2860
Q24289511-97499B75-89A1-464C-AF63-04CC74AAEBD8Q27001743-FF455B9A-B805-4245-9BDD-7433F38AE116Q28360981-BFD6D3A9-6E7D-402B-9BA6-00E58ED737F8Q31117154-0665B94C-D7D7-471C-8B87-BC2E876CBB41Q34049616-F7247642-EE11-43DA-8E59-6E02B36CD431Q34164506-9B8FEA7B-B724-48AD-9BB4-7EC96FFF5455Q34486088-97E8E3EE-85F4-49D8-9EA0-A195176DFC76Q34671352-02EE60AB-C08E-424A-A530-5692703566FFQ34692616-0BBA3868-B5E1-40A0-A224-3175366573EBQ36370956-ADFF9352-627C-4FCB-8B40-86C3A82708B9Q36802175-C8784AFF-3EFB-4492-885F-39091A6E82ECQ36980763-A99E4DEF-A3E7-4C29-AF32-9C5169BF2DB5Q37374561-B3BDB14A-B00C-45DD-8AE2-E8415ACEFDF6Q38078689-F08B15BB-3965-4874-BF67-10293ECF3E8FQ38876580-56EC2A22-0F19-4D07-B5D0-E611E513D2A5Q39185937-EE453449-7AA2-4AF1-9CCE-60DFAC2D8645Q40781838-300960E9-A3BC-455C-8DB5-29C61486D897Q41087116-FAC4D182-5068-444D-80E1-B09284C28957Q41762734-452DF21F-178D-4C78-9EF2-C821A9F86AB6Q42260800-12B909D0-7AFD-4617-B99D-9B59526EC837Q42343539-64ADBE5E-36CB-43F4-AB46-A25CD4A66D2EQ44695275-CCF20364-1593-4AAB-8793-C1B6BAC3FF81Q46387478-BFD8F810-BF82-4E06-9CF4-20D4D86D17DDQ46925588-800609AE-0DE7-4055-9ED8-D691FD2E159BQ50512941-6E991F64-357F-4733-8D21-D810BA5AA0C5Q57898104-59264F0F-1260-48C3-84FB-5E349EC32202
P2860
Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@ast
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@en
type
label
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@ast
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@en
prefLabel
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@ast
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@en
P2093
P2860
P356
P1476
Inhibition of autoimmune neuro ...... t with an iron-chelating agent
@en
P2093
P2860
P304
P356
10.1084/JEM.160.5.1532
P407
P577
1984-11-01T00:00:00Z